- Report
- October 2024
- 96 Pages
Global
From €3500EUR$4,272USD£3,134GBP
- Report
- October 2023
- 91 Pages
Global
From €3500EUR$4,272USD£3,134GBP
- Report
- July 2023
- 84 Pages
Global
From €3500EUR$4,272USD£3,134GBP
- Report
- May 2022
- 78 Pages
Global
From €3500EUR$4,272USD£3,134GBP
- Report
- October 2024
- 83 Pages
Global
From €3500EUR$4,272USD£3,134GBP
- Report
- June 2022
- 84 Pages
Global
From €3500EUR$4,272USD£3,134GBP
- Report
- November 2022
- 63 Pages
Global
From €1755EUR$2,000USD£1,519GBP
- Report
- November 2022
- 76 Pages
Global
From €1755EUR$2,000USD£1,519GBP
- Report
- September 2022
- 54 Pages
Global
From €1755EUR$2,000USD£1,519GBP
- Report
- March 2023
- 100 Pages
Africa
From €1755EUR$2,000USD£1,519GBP
- Report
- April 2025
- 211 Pages
China
From €3510EUR$4,000USD£3,037GBP
Proton Pump Inhibitors (PPIs) are a class of drugs used to treat Gastrointestinal (GI) disorders. They work by reducing the amount of acid produced in the stomach, which helps to relieve symptoms of acid reflux, heartburn, and other GI conditions. PPIs are available in both prescription and over-the-counter forms, and are often used in combination with other medications to treat more severe GI conditions. Common side effects of PPIs include headache, nausea, and diarrhea.
PPIs are among the most widely prescribed drugs in the world, and are used to treat a variety of GI conditions. They are often used as a first-line treatment for acid reflux and other GI disorders, and are also used to prevent and treat ulcers.
Some of the major companies in the PPI market include AstraZeneca, Pfizer, Takeda, and GlaxoSmithKline. These companies produce a variety of PPIs, including omeprazole, lansoprazole, and pantoprazole. Show Less Read more